Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Παρόμοια τεκμήρια

• Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
  ανά: Kim, Eun Young, κ.ά.
  Έκδοση: (2018)
• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  ανά: Suda, Kenichi, κ.ά.
  Έκδοση: (2021)
• Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness
  ανά: Hirsh, Vera, κ.ά.
  Έκδοση: (2020)
• Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
  ανά: Gelatti, Ana, κ.ά.
  Έκδοση: (2019)
• Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
  ανά: Becker, Kevin, κ.ά.
  Έκδοση: (2014)